argenx to Participate at Upcoming Investor Conferences

Company Overview - Argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, which is available in multiple regions including the U.S., Japan, Israel, the EU, the UK, China, and Canada [3] - Argenx is actively evaluating its drug efgartigimod in various serious autoimmune diseases and is advancing several earlier-stage experimental medicines [3] Upcoming Events - Members of the management team will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 2:30 p.m. ET in Boston, MA [1] - Management will also engage in investor meetings at the Jefferies London Healthcare Conference on November 20 and 21, 2024, in London, UK [2] - A live webcast of the Guggenheim fireside chat will be available on the company's investor website, with a replay accessible for approximately 90 days [2]